Dengue serotype 2 attenuated strain

Abstract

The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.

What is claimed is: 
     
         1 . An isolated polyprotein encoded by SEQ ID No.1, or fragments thereof that comprise at least an arginine at position 9 of M protein, and/or a glutamic acid at position 228 of E protein, and/or a threonine at position 69 of NS3 protein, and/or a histidine at position 181 of NS3 protein, and/or a lysine at position 541 of NS5 protein, and/or a threonine at position 832 of NS5 protein. 
     
     
         2 . The isolated polyprotein or fragments thereof according to  claim 1 , wherein the polyprotein is the polyprotein of sequence SEQ ID No. 2. 
     
     
         3 . A fragment of the polyprotein according to  claim 1  which is at least 20 amino acids long. 
     
     
         4 . A fragment of the polyprotein according to  claim 1  which comprises M protein, and/or E protein, and/or NS3 protein, and/or NS5 protein.